7/30/2019 Oncology - Esophageal Ca

1/18

14- , 2-5% . 2004

7124, 75,4% . 2003 66,7%.

,( 6,8 6,7 100 . ),

7/30/2019 Oncology - Esophageal Ca

2/18

1. (15.0):

(

), 18 .

2. )(15.3),

24 ;

)(15.4)

-.

32;

)(15.5) 8

()

-.

40 .

7/30/2019 Oncology - Esophageal Ca

3/18

, ;

,, .

7/30/2019 Oncology - Esophageal Ca

4/18

7/30/2019 Oncology - Esophageal Ca

5/18

7/30/2019 Oncology - Esophageal Ca

6/18

; ; ,

( 8 ); (skip metastasis) , 30% , 23% .

7/30/2019 Oncology - Esophageal Ca

7/18

, : , ; , ;

,

7/30/2019 Oncology - Esophageal Ca

8/18

TNM (6- , 2002 .)

-

0 Tis (Carcinoma in

situ)1

2

3

4

0 1

1 1b 1 1b 1 1b

N N N0 N1

7/30/2019 Oncology - Esophageal Ca

9/18

:

7/30/2019 Oncology - Esophageal Ca

10/18

+ :192 , 3 33+ :5-

10% ( 9%)(EORTC,1982 )

+: 85% 70%,

: 130 60 +(-)5Fu/mitomicin-C. 2- 30% 12%, 14,9. 9,0 . (ECOG,1990)

: 1- 18%, 5- 6%(Fisher SA, Brady LW. Esophagus. In: Perez CA, Brady LW, eds. Principlesand practice of radiation oncology,3rd ed.,1998)

7/30/2019 Oncology - Esophageal Ca

11/18

5-

6( 8) , 18-20.

, (, ,), 60-70, 46-

50.

7/30/2019 Oncology - Esophageal Ca

12/18

,

7/30/2019 Oncology - Esophageal Ca

13/18

7/30/2019 Oncology - Esophageal Ca

14/18

7/30/2019 Oncology - Esophageal Ca

15/18

7/30/2019 Oncology - Esophageal Ca

16/18

.

7/30/2019 Oncology - Esophageal Ca

17/18

.

7/30/2019 Oncology - Esophageal Ca

18/18

:

a) ;b) , 9;c) , 4